Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
7 studies found for:    9500606 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
Conditions: Melanoma;   Neoplasm Metastasis
Interventions: Drug: GP100 peptide;   Drug: IL-2
2 Completed Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
Conditions: Melanoma;   Neoplasm Metastasis
Intervention: Biological: Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
3 Completed A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
Condition: Melanoma
Intervention: Biological: gp100 human melanoma peptide
4 Unknown  Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention: Biological: URLC10, TTK and KOC1
5 Completed Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Condition: Melanoma
Interventions: Drug: cyclophosphamide;   Biological: Mature dendritic cell vaccine
6 Unknown  Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer
Condition: Esophageal Cancer
Intervention: Biological: URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil
7 Suspended Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer
Condition: Bile Duct Cancer
Interventions: Biological: Peptide vaccine for URLC10;   Drug: Gemcitabine

Study has passed its completion date and status has not been verified in more than two years.